You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
A concise, up-to-date clinician's guide to cancer management -- from the leaders in the field A Doody's Core Title! The MD Anderson Cancer Center is ranked as the world's leading institution in cancer medicine. With publication of the MD Anderson Manual of Medical Oncology, the editorial board of this prestigious institution makes available for the first time a resource that meets the needs of clinicians for an authoritative, accessible guide to the medical management of patients with cancer and its complications. Straight-to-the-point, state-of-the-art strategies for cancer management Gives physicians a current, coherent approach to each disease and situation -- imbued with the clinical exp...
Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials. Topics include: Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors) Ras inhibitors Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors) Lenalidomide analogs New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib) New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40) Thrombopoietic agents Leukemias: Principles and Practice of Therapy Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area
Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.
Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.
Despite intense political focus and debate for the past 10 years, Americans remain deeply worried about the availability and affordability of health care for themselves and their families. In clear and accessible prose, journalist Ryan Holeywell and medical doctor and health policy expert Arthur Garson provide Americans with the tools we need to have an honest, unbiased view of the state of health care policy in America. By fact checking 20 enduring health care myths they move the debate beyond Obamacare v. repeal and replace and give citizens the tools they need to evaluate the major policy issues confronting our health care system.
Expert, hands-on guidance for the practicing oncologist—from the leader in the field of cancer management—completely updated to reflect the latest advances A Doody's Core Title for 2023! Comprehensive and authoritative, The MD Anderson Manual of Medical Oncology delivers everything you need to accurately diagnose and effectively treat a wide range of cancers—including leukemia, lymphoma, myeloma, lung and breast cancer, genitourinary carcinoma, melanoma, and sarcoma. This unmatched resource emphasizes practical, actionable steps to cancer treatment, providing "to the point" recommendations, chapter summary boxes, tables, charts, expert opinion and patient education boxes, practice tips...
Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.
Biomedical patents have been the subject of heated debate. Regulatory agencies such as the European Patent Office make small decisions with big implications, which escape scrutiny and revision, when they decide who has access to expensive diagnostic tests, whether human embryonic stem cells can be traded in markets, and under what circumstances human health is more important than animal welfare. Moreover, the administration of the Trade Related Aspects of Intellectual Property Rights by the World Trade Organization has raised considerable disquiet as it has arguably created grave health inequities. Those doubting the merits of the one size fits all approach ask whether priority should be giv...
Public debate on the rising cost of new biotechnology drug treatments has intensified over the last few years as healthcare budget pressures have mounted under a strained economy. Meanwhile, the demand for new, effective medical and drug treatments continues to rise as unhealthy lifestyles cause further increases in diabetes and cardiovascular disease. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than g...